Wells Fargo raised the firm’s price target on Zymeworks (ZYME) to $14 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks upgraded to Overweight on 2025 pipeline at JPMorgan
- Zymeworks upgraded to Overweight from Neutral at JPMorgan
- Zymeworks Advances Oncology and Expands Therapeutic Reach
- Zymeworks hosts R&D day highlighting continued clinical progress
- Zymeworks to Showcase Innovations at Investor Conferences